MX393455B - Anticuerpos anti-cd40 y sus usos. - Google Patents

Anticuerpos anti-cd40 y sus usos.

Info

Publication number
MX393455B
MX393455B MX2018014630A MX2018014630A MX393455B MX 393455 B MX393455 B MX 393455B MX 2018014630 A MX2018014630 A MX 2018014630A MX 2018014630 A MX2018014630 A MX 2018014630A MX 393455 B MX393455 B MX 393455B
Authority
MX
Mexico
Prior art keywords
antibodies
present disclosure
making
methods
nucleic acids
Prior art date
Application number
MX2018014630A
Other languages
English (en)
Other versions
MX2018014630A (es
Inventor
Diane Hollenbaugh
Diane Sau Mun COHEN
Shiming Ye
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of MX2018014630A publication Critical patent/MX2018014630A/es
Publication of MX393455B publication Critical patent/MX393455B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos anticuerpos anti-CD40, composiciones que los incluyen, ácidos nucleicos que los codifican, y métodos para su elaboración y su uso.
MX2018014630A 2016-05-27 2017-05-26 Anticuerpos anti-cd40 y sus usos. MX393455B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342417P 2016-05-27 2016-05-27
PCT/US2017/034681 WO2017205742A1 (en) 2016-05-27 2017-05-26 Anti-cd40 antibodies and their uses

Publications (2)

Publication Number Publication Date
MX2018014630A MX2018014630A (es) 2019-06-10
MX393455B true MX393455B (es) 2025-03-24

Family

ID=59014833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014630A MX393455B (es) 2016-05-27 2017-05-26 Anticuerpos anti-cd40 y sus usos.

Country Status (35)

Country Link
US (8) US10519243B2 (es)
EP (2) EP3995511A1 (es)
JP (2) JP2019523221A (es)
KR (2) KR20220028143A (es)
CN (1) CN109476750B (es)
AR (2) AR108611A1 (es)
AU (1) AU2017271602A1 (es)
BR (1) BR112018074468A2 (es)
CA (1) CA3025347A1 (es)
CL (1) CL2018003366A1 (es)
CO (1) CO2018012699A2 (es)
CR (1) CR20180605A (es)
CY (1) CY1124806T1 (es)
DO (1) DOP2018000258A (es)
EC (1) ECSP18094829A (es)
ES (1) ES2901722T3 (es)
HR (1) HRP20211882T1 (es)
HU (1) HUE056670T2 (es)
IL (1) IL263223B2 (es)
LT (1) LT3464361T (es)
MX (1) MX393455B (es)
MY (1) MY195442A (es)
NZ (1) NZ748644A (es)
PE (1) PE20190970A1 (es)
PH (1) PH12018502456A1 (es)
PL (1) PL3464361T3 (es)
PT (1) PT3464361T (es)
RS (1) RS62726B1 (es)
RU (1) RU2752049C2 (es)
SG (2) SG10201914132RA (es)
SI (1) SI3464361T1 (es)
SM (1) SMT202100721T1 (es)
TW (2) TWI761348B (es)
UA (1) UA123111C2 (es)
WO (1) WO2017205742A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0819229B1 (pt) * 2007-11-01 2019-01-22 The Board Of Trustees Of The University Of Arkansas vacinas para reforçar reações imunes contra eimeria
BR112018074468A2 (pt) * 2016-05-27 2019-03-06 Abbvie Biotherapeutics Inc. anticorpos anti-cd40 e suas utilizações
KR20210005082A (ko) * 2018-04-20 2021-01-13 리브젠 바이오파마 코., 엘티디. 항-cd40 항체 및 이의 용도
IL283279B2 (en) 2018-11-23 2025-08-01 Strike Pharma Ab Bi-specific conjugates
AU2019389354A1 (en) * 2018-11-30 2021-07-15 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
CN111548415B (zh) * 2019-03-04 2021-04-20 北京天广实生物技术股份有限公司 与cd40特异结合的抗体及其用途
KR20220004985A (ko) 2019-03-27 2022-01-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd40 활성화 특성을 가진 재조합 단백질
JP7535060B2 (ja) * 2019-04-10 2024-08-15 ナンカイ ユニバーシティ 抗ｃｄ４０抗体およびその使用
GB201910900D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
AU2019465294A1 (en) * 2019-09-11 2022-03-24 Novartis Ag A method for preventing human virus associated disorders in patients
JP2022553108A (ja) * 2019-10-23 2022-12-21 リビジェン バイオファーマ ホールディングス リミテッド 抗ｃｄ４０結合分子およびそのようなものを含む二重特異性抗体
CA3157516A1 (en) * 2019-11-08 2021-05-14 Xinyan Zhao Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
WO2021110562A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
EP4185320A4 (en) * 2020-07-23 2025-10-08 Dyne Therapeutics Inc MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
TWI863317B (zh) * 2022-05-31 2024-11-21 大陸商明濟生物製藥(北京)有限公司 抗cd40抗體和抗pd-l1×cd40雙特異抗體及其應用
EP4590717A1 (en) * 2022-09-20 2025-07-30 Currus Biologics Pty Ltd Bispecific polypeptides and uses thereof
TW202500587A (zh) * 2023-02-16 2025-01-01 法商賽諾菲公司 Cd40結合蛋白

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
ES2172149T3 (es) 1997-04-14 2002-09-16 Micromet Ag Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE384792T1 (de) 1998-11-18 2008-02-15 Genentech Inc Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU2001236621B2 (en) 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2551008C (en) * 2003-12-25 2013-10-01 Kirin Beer Kabushiki Kaisha Anti-cd40 antibody mutants
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006017173A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
US8323653B2 (en) * 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2009048537A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Humanized antibody
DK3178851T3 (da) * 2010-03-31 2020-07-27 Boehringer Ingelheim Int Anti-cd40-antistoffer
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
MX371442B (es) 2012-08-24 2020-01-30 Chugai Pharmaceutical Co Ltd VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
EP3925977A1 (en) * 2012-10-30 2021-12-22 Apexigen, Inc. Anti-cd40 antibodies and methods of use
CA2904528C (en) 2013-03-15 2021-01-19 Abbvie Biotherapeutics Inc. Fc variants
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
SG11201702598XA (en) 2014-10-29 2017-05-30 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
SI3303395T1 (sl) * 2015-05-29 2020-03-31 Abbvie Inc. Protitelesa proti CD40 in njihove uporabe
BR112018074468A2 (pt) * 2016-05-27 2019-03-06 Abbvie Biotherapeutics Inc. anticorpos anti-cd40 e suas utilizações
JP2019519223A (ja) * 2016-05-27 2019-07-11 アッヴィ・バイオセラピューティクス・インコーポレイテッド 免疫調節タンパク質及び腫瘍抗原に結合する二重特異性結合タンパク質

Also Published As

Publication number Publication date
CN109476750A (zh) 2019-03-15
AU2017271602A1 (en) 2018-12-13
US20210024642A1 (en) 2021-01-28
SMT202100721T1 (it) 2022-01-10
PE20190970A1 (es) 2019-07-09
CL2018003366A1 (es) 2019-03-15
AR124692A2 (es) 2023-04-26
SI3464361T1 (sl) 2022-01-31
US20180186889A1 (en) 2018-07-05
PL3464361T3 (pl) 2022-01-31
MX2018014630A (es) 2019-06-10
US10400041B2 (en) 2019-09-03
CA3025347A1 (en) 2017-11-30
PH12018502456A1 (en) 2019-10-21
TW201806971A (zh) 2018-03-01
HRP20211882T1 (hr) 2022-03-04
US20220119542A1 (en) 2022-04-21
SG10201914132RA (en) 2020-03-30
IL263223B (en) 2022-11-01
SG11201810522UA (en) 2018-12-28
US20200040090A1 (en) 2020-02-06
KR102366355B1 (ko) 2022-02-24
HUE056670T2 (hu) 2022-02-28
NZ748644A (en) 2023-05-26
RS62726B1 (sr) 2022-01-31
KR20190014524A (ko) 2019-02-12
IL263223B2 (en) 2023-03-01
IL263223A (en) 2018-12-31
BR112018074468A2 (pt) 2019-03-06
RU2018146533A (ru) 2020-06-29
CN109476750B (zh) 2022-02-01
EP3995511A1 (en) 2022-05-11
TW202229356A (zh) 2022-08-01
AR108611A1 (es) 2018-09-05
LT3464361T (lt) 2022-01-10
US20170342159A1 (en) 2017-11-30
JP2022068294A (ja) 2022-05-09
CY1124806T1 (el) 2022-11-25
DOP2018000258A (es) 2019-02-15
WO2017205742A1 (en) 2017-11-30
KR20220028143A (ko) 2022-03-08
EP3464361B1 (en) 2021-11-10
JP2019523221A (ja) 2019-08-22
TWI761348B (zh) 2022-04-21
CR20180605A (es) 2020-01-13
JP7331179B2 (ja) 2023-08-22
EP3464361A1 (en) 2019-04-10
ES2901722T3 (es) 2022-03-23
US10519243B2 (en) 2019-12-31
US10844131B2 (en) 2020-11-24
UA123111C2 (uk) 2021-02-17
RU2018146533A3 (es) 2020-06-29
US20210277137A1 (en) 2021-09-09
RU2752049C2 (ru) 2021-07-22
US20200010558A1 (en) 2020-01-09
US10023645B1 (en) 2018-07-17
ECSP18094829A (es) 2019-03-29
PT3464361T (pt) 2021-12-27
MY195442A (en) 2023-01-21
TWI814279B (zh) 2023-09-01
CO2018012699A2 (es) 2019-08-20
US10597460B2 (en) 2020-03-24
US20190071509A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
MX393455B (es) Anticuerpos anti-cd40 y sus usos.
CY1123642T1 (el) Αντισωματα enanti-pd-1
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
CO2017011238A2 (es) Anticuerpos anti-c1s humanizados
ECSP17023281A (es) Inhibidores de mk2 y sus usos
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
MX377774B (es) Formulaciones de proteinas.
EA202091567A1 (ru) Химерные белки мти
CL2017001172A1 (es) Anticuerpos anti-interleukin-33 y sus usos